Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®

C. Vilaplana, E. Montané, S. Pinto, A. M. Barriocanal, G. Domenech, F. Torres, P. J. Cardona, Joan Costa

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

109 Cites (Scopus)

Resum

A Phase I interventional Clinical Trial was performed with a potential tuberculosis vaccine, based on detoxified cellular fragments of M. tuberculosis, named RUTI®. The objective was to evaluate the safety profile and T-cell immune responses over a 6-month period following subcutaneous inoculation. The double-blind, randomized and placebo-controlled trial was conducted in healthy volunteers, all recruited at one site. RUTI®, at each of the four tested doses, starting from 5 μg and going up to 200 μg, and placebo were inoculated to groups of 4 and 2 volunteers respectively, consecutively. RUTI® appeared to be well tolerated as judged by local and systemic clinical evaluation, though vaccine dose dependent local adverse reactions were recorded. T-cell responses of blood lymphocytes to PPD and a number of antigen subunits were elevated, when compared with controls subjects. These results support the feasibility of future evaluation, to be targeted at subjects with latent tuberculosis infection (LTBI). © 2009 Elsevier Ltd. All rights reserved.
Idioma originalEnglish
Pàgines (de-a)1106-1116
RevistaVaccine
Volum28
Número4
DOIs
Estat de la publicacióPublicada - 22 de gen. 2010

Fingerprint

Navegar pels temes de recerca de 'Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®'. Junts formen un fingerprint únic.

Com citar-ho